Routine Transcervical Thymectomy in MEN-1 Patients

Revisiting the Evidence for Routine Transcervical Thymectomy for the Prevention of Thymic Carcinoid Tumours in MEN-1 Patients a Case Series

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05061784

Enrollment

Registered

2021-09-30

Start date

2021-07-14

Completion date

2021-08-20

Last updated

2021-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Endocrine Neoplasia Type 1 (MEN-1), Thymic Carcinoid

Keywords

Routine transcervical thymectomy

Brief summary

A case series was built after review of available literature by searching four databases (PubMed, Embase, Medline and Cochrane Library) for observational studies or case reports on routine prophylactic TCT for MEN-1 and the development of thymic carcinoids.

Detailed description

Introduction and Importance Malignant thymic carcinoids are uncommon but important entities among patients with multiple endocrine neoplasia type 1 (MEN-1). Current treatment guidelines advise the performance of a routine transcervical thymectomy (TCT) during parathyroidectomy, to prevent its development, although data on the yield of this prophylactic TCT is scarce. We aimed to revisit available literature to investigate and summarize the efficacy of routine TCT during neck exploration for parathyroidectomy, for the prevention of thymic carcinoid tumours among MEN-1 patients. Methods A case series was built after review of available literature by searching four databases (PubMed, Embase, Medline and Cochrane Library) for observational studies or case reports on routine prophylactic TCT for MEN-1 and the development of thymic carcinoids.

Interventions

PROCEDURERoutine thymectomy, which has been performed

There is no intervention

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Studies including MEN-1 patients who underwent a routine thymectomy during parathyoidectomy * We accepted randomized controlled trials or observational studies that included patients of any age who underwent a routine TCT in the setting for MEN-1, published as full-length articles in peer-reviewed journals, which mentioned data on thymic carcinoid tumours.

Exclusion criteria

* We excluded reviews, letters, conference proceedings and non-English publications.

Design outcomes

Primary

Measure	Time frame	Description
Incidence of thyme carcinoid	The timeframe will be from date of transcervical thymectomy until the date of documented diagnosis of diagnosis of thymic NET; progression of disease or date of death from any cause, whichever came first, assessed up to 100 months.	Retrospective review of published studies

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026